Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Systematically Mediastinal Lymph Node Dissection (SLND) Versus Non-Dissection Following Endoscopic Submucosal Dissection (ESD) for T1a Stage Esophageal Squamous Cell Carcinoma

NCT06979986 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT06979986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06979986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Systematically Mediastinal Lymph Node Dissection (SLND) Versus Non-Dissection Following Endoscopic Submucosal Dissection (ESD) for T1a Stage Esophageal Squamous Cell Carcinoma
Lead sponsor
Fujian Cancer Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 1, 2025
Completion date
April 1, 2027
Enrollment
102 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer